Torrent Pharma: Morgan Stanley maintains an Equal Weight on Torrent Pharma with a Target Price of ₹4580, citing in-line Q4 EBITDA, strong 15% India growth, semaglutide gaining 38% market share with FY27 sales guidance of ₹2–2.5bn, and JB Pharma merger synergies of ₹4–4.5bn progressing as planned.

 25 May 2026 09:02 AM

Torrent Pharma: Morgan Stanley maintains an Equal Weight on Torrent Pharma with a Target Price of ₹4580, citing in-line Q4 EBITDA, strong 15% India growth, semaglutide gaining 38% market share with FY27 sales guidance of ₹2–2.5bn, and JB Pharma merger synergies of ₹4–4.5bn progressing as planned.

Torrent Pharma: Jefferies maintains a Buy on Torrent Pharma with a Target Price of ₹5350, citing steady India growth of 15% YoY, in-line core performance excluding JB Pharma consolidation, and strong progress on JB Pharma integration with expected first-year cost synergy benefits on track.

 25 May 2026 09:02 AM

Torrent Pharma: Jefferies maintains a Buy on Torrent Pharma with a Target Price of ₹5350, citing steady India growth of 15% YoY, in-line core performance excluding JB Pharma consolidation, and strong progress on JB Pharma integration with expected first-year cost synergy benefits on track.

Torrent Pharma: Plans To Expand Its India Field Force To 7,500 Members By FY '27, With No Further Growth Expected After Merging Full JB MR Strength. Semaglutide Sales In India Are Estimated To Hit INR 200-250 Crore In The First Year, Presenting A Much Bigger Opportunity Compared To Past Launches Like Sitagliptin That Reached INR 70-75 Crore.

 25 May 2026 09:04 AM

Torrent Pharma: Plans To Expand Its India Field Force To 7,500 Members By FY '27, With No Further Growth Expected After Merging Full JB MR Strength. Semaglutide Sales In India Are Estimated To Hit INR 200-250 Crore In The First Year, Presenting A Much Bigger Opportunity Compared To Past Launches Like Sitagliptin That Reached INR 70-75 Crore.

Torrent Pharma: Projects Low Single-Digit Growth Below 5% For German Business Next Year, R&D Spending Around 5% For FY '26, With A 0.5% Increase Planned Mainly For India And The U.S.

 25 May 2026 09:04 AM

Torrent Pharma: Projects Low Single-Digit Growth Below 5% For German Business Next Year, R&D Spending Around 5% For FY '26, With A 0.5% Increase Planned Mainly For India And The U.S.

Torrent Pharma: Expects U.S. Growth In Single Digits While Brazil Sees Double-Digit Growth Of 10% To 15% For Next Year

 25 May 2026 09:04 AM

Torrent Pharma: Expects U.S. Growth In Single Digits While Brazil Sees Double-Digit Growth Of 10% To 15% For Next Year

Torrent Pharma: Confirms Cost Synergy Progress From JB Pharma Deal, Projecting INR 450 Crores By Year Three. Expected Savings Include 20% In Year One, 60% To 80% Cumulative By Year Two, And Remaining 20% In Year Three. Margin Growth For Merged Company Exceeds Expectations As Some Costs Were Cut Earlier Than Planned.

 25 May 2026 09:05 AM

Torrent Pharma: Confirms Cost Synergy Progress From JB Pharma Deal, Projecting INR 450 Crores By Year Three. Expected Savings Include 20% In Year One, 60% To 80% Cumulative By Year Two, And Remaining 20% In Year Three. Margin Growth For Merged Company Exceeds Expectations As Some Costs Were Cut Earlier Than Planned.

Torrent Pharma: Expects Strong Growth In India, Fueled By Semaglutide Launch And Ongoing Strength In Curatio And Chronic Businesses, Along With New First-To-Market Products. They Anticipate A Better Year For Organic Growth Compared To Last Year, Provided There Are No Geopolitical Demand Shocks.

 25 May 2026 09:05 AM

Torrent Pharma: Expects Strong Growth In India, Fueled By Semaglutide Launch And Ongoing Strength In Curatio And Chronic Businesses, Along With New First-To-Market Products. They Anticipate A Better Year For Organic Growth Compared To Last Year, Provided There Are No Geopolitical Demand Shocks.

TORRENT PHARMACEUTICALS: Q4 CONS NET PROFIT 3.9B RUPEES VS 4.98B (YOY) || Q4 REVENUE 41.3B RUPEES VS 29.6B (YOY)

 22 May 2026 05:03 PM

TORRENT PHARMACEUTICALS: Q4 CONS NET PROFIT 3.9B RUPEES VS 4.98B (YOY) || Q4 REVENUE 41.3B RUPEES VS 29.6B (YOY)

TORRENT PHARMACEUTICALS: Q4 EBITDA 12.7B RUPEES VS 9.64B (YOY) || Q4 EBITDA MARGIN 30.77% VS 32.58% (YOY)

 22 May 2026 05:03 PM

TORRENT PHARMACEUTICALS: Q4 EBITDA 12.7B RUPEES VS 9.64B (YOY) || Q4 EBITDA MARGIN 30.77% VS 32.58% (YOY)